Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Company Deals

Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026
Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Deals

LinkedCare Raises Hundreds of Millions in Series E Funding Led by State-Owned Investors

Fineline Cube Jan 8, 2025

LinkedCare, a consumer healthcare SaaS+ supply chain platform based in Shanghai, has reportedly raised “hundreds...

Company Deals

Grand Life Sciences Partners with Cali Biosciences for CPL-01 Commercialization in China

Fineline Cube Jan 8, 2025

China-based Grand Life Sciences has entered into a partnership with compatriot firm Cali Biosciences Co.,...

Company Drug

Insilico Medicine’s ISM5411 Shows Positive Results in Phase I Studies for Inflammatory Bowel Disease

Fineline Cube Jan 8, 2025

China’s generative artificial intelligence (AI)-driven biotech, Insilico Medicine, has announced positive preliminary results from two...

Company Deals

GlycoNex Licenses SPD8 Biosimilar to Undisclosed Company for Osteoporosis Treatment

Fineline Cube Jan 8, 2025

Taiwan-based GlycoNex, Inc. (TPEx: 4168) has announced a licensing agreement with an undisclosed company for...

Company Drug

Yiling Pharmaceutical Withdraws Clinical Filing for G201-Na in Assisted Reproduction

Fineline Cube Jan 8, 2025

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced the withdrawal of its clinical filing...

Company Drug

Dizal’s Sunvozertinib Receives Priority Review from FDA for EGFR Exon 20 NSCLC

Fineline Cube Jan 8, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...

Company Deals

Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta

Fineline Cube Jan 8, 2025

Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro’s proprietary...

Company Deals

Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases

Fineline Cube Jan 8, 2025

US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE:...

Company Deals

AbbVie Exercises Option for Capsida’s Neurodegenerative Disease Program

Fineline Cube Jan 8, 2025

US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option...

Company Medical Device

Eyebright Medical’s Loong Crystal PR Receives NMPA Class III Medical Device Approval

Fineline Cube Jan 8, 2025

China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050) has announced that it has received...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approvals for ADC SYS6045 and PDE4B Inhibitor SYH2059

Fineline Cube Jan 8, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received separate clinical...

Company Drug

Kelun-Biotech’s Anti-HER2 ADC A166 Receives NMPA Review for Expanded Indication

Fineline Cube Jan 8, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that another indication approval filing for...

Company Deals

PostEra Expands Partnership with Pfizer to Launch New ADC Collaboration

Fineline Cube Jan 8, 2025

PostEra, a Boston-based biotech company powered by machine learning, has announced an expanded partnership with...

Company Deals

Merck KGaA Adopts Quris AI’s Bio-AI Platform for Drug Development Pipeline

Fineline Cube Jan 8, 2025

Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced...

Company Drug

Hansoh and GSK’s HS-20093 Receives FDA Breakthrough Therapy Designation for Osteosarcoma

Fineline Cube Jan 8, 2025

China-based Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692) and its UK partner GSK plc (LON:...

Company Deals

Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co. Launch Strategic Partnership for Linagliptin

Fineline Cube Jan 7, 2025

On January 7, Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607,...

Company Deals

Merck KGaA Completes Acquisition of HUB Organoids, Expanding Cell Culture Portfolio

Fineline Cube Jan 7, 2025

German major Merck KGaA (ETR: MRK) announced the completion of its acquisition of Holland-based HUB...

Company Drug

Amgen’s Imdylltra Gains Conditional Approval in UK for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Jan 7, 2025

US biotech company Amgen (NASDAQ: AMGN) has received conditional approval from the UK’s Medicines and...

Company Deals

Mabwell Bioscience Files for IPO on Hong Kong Stock Exchange, Expanding Biopharma Reach

Fineline Cube Jan 7, 2025

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has officially filed for an initial public offering...

Company Deals

WuXi Biologics to Sell Irish Vaccine Assets to MSD for USD 500 Million

Fineline Cube Jan 7, 2025

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) is poised to...

Posts pagination

1 … 255 256 257 … 688

Recent updates

  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
  • AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx
  • Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results
  • Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Company Medical Device

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.